Full text Pdf 

 

http://doi.org/10.31288/oftalmolzh201146770

PECULIARITIES OF PHARMACOKINETICS OF TRIAMCINOLONE ACETONIDE IN ITS INTRASCELRAL AND SUBTENON INTRODUCTION

Bezdetko P. A., Zavoloka O. V., Dovzhuk T. N.

Kharkov, Ukraine

80 crawls (40 in every group) were operated with intrascleral or sub-tenon's introductions of TA. 3 hours, 1, 3, 7, 14 days and 1, 2, 3, 6, 7 months later after injection 4 crawls were killed in every group. Concentration of TA was determined in blood plasma, intraocular liquid, and also in intraocular fabrics (vitreous body, retinochoroid layer) by the method of liquid chromatography. TA was determined more long in case of intrascleral method of introductions in a retinochoroid layer (6 months), vitreous body and intraocular liquid (3 months) compared to subtenon (2 and 1 month accordingly), thus at both methods of introduction in a retinochoroid layer preparation was saved maximally; in a blood plasma TA was determined less long (7 days) compared to sub-tenon's (14 days).

References

1.Kim Y. M., Lim J. O., Kim H. K. et al. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide // European Journal of Pharmaceutics and Biopharmaceutics. — 2008. — Vol. 70. — P. 179- 186.
Crossref

2.Robinson M. R., LeeS. S., Kim H. et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide // Experimental Eye Research. —2006. — Vol. 82 (3). — P. 479-487.
Crossref

3.Kim H., Galbn C. J., Lutz R. J. et al. Assessment of Subcon-junctival and Intrascleral Drug Delivery to the Posterior Segment Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Stephanie // Investigative Ophthalmology and Visual Science. — 2007. — Vol. 48. — P. 808- 814.
Crossref

4.Cheng L., Hostetler K. Y., Lee J. et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir // Investigative Ophthalmology and Visual Science. —2004. — Vol.45. — P.4138-4144.
Crossref

5.Nan K. , Sun S. , Li Y. et al. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection // British Journal of Ophthalmology. — 2010. — Vol. 94. — P. 654- 658.C
Crossref

6.GarcHa-ArumH J. , Boixadera A. , Giralt J. et al. Comparison of different techniques for purification oftriamcinolone acetonide suspension for intravitreal use // British Journal of Ophthalmology. — 2005. — Vol. 89. — P. 1112-1114.
Crossref

7.Kim H., Robinson M. R., Lizak M. J. et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging // Investigative Ophthalmology and Visual Science. —2004. — Vol. 45. — P. 2722-2731.
Crossref

8.Pontes de Carvalho R. A., Krausse M. L., Murphree A. L. et al. Delivery from episcleral exoplants // Investigative Ophthalmology and Visual Science. — 2006. — Vol.47. —P. 4532-4539.
Crossref

9.Ghosn M. G., Tuchin V. V., Larin K. V. Nondestructive Quantification of Analyte Diffusion in Cornea and Sclera Using Optical Coherence Tomography // Investigative Ophthalmology and Visual Science. — 2007. — Vol.48. —P. 2726-2733.
Crossref

10.Bonini-Filho T. M. A., Jorge R., Barbosa J. C. et al. Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema: A Randomized Clinical // Investigative Ophthalmology and Visual Science. — 2005. — Vol. 46. — P. 3845-3849.

11.Cellini M., Pazzaglia A., Zamparini E. et al. Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema // BMC Ophthalmology. — 2008. — Vol. 8. — P. 5.

12.Ghate D., Brooks W., McCarey B. E. et al. Pharmacokinetics of Intraocular Drug Delivery by Periocular Injections Using Ocular Fluorophotometry // Investigative Ophthalmology and Visual Science. — 2007. — Vol. 48. — P. 2230-2237.

13.Sallam A., Jayakumar S., Lightman S.Intraocular delivery of anti-infective drugs-bacterial, viral, fungal and parasitic // Recent Patents on Anti-Infective Drug Discovery. — 2008. — Vol. 3 (1). — P. 53- 63.

14.Short B. G. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations // Toxicologic Pathology. — 2008. — Vol. 36 (1). — P. 49- 62.